GENEVA: The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

Geneva: The global fight against AIDS faces a severe setback following the abrupt halt of US foreign aid funding, the UN's ...

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

UNAIDS Executive Director Winnie Byanyima said the sudden loss of American money has been 'devastating' for efforts to stop ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...

The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...